Pickering Gisèle, Voute Marion, Sorel Marc, Pereira Bruno, Riant Thibault
University Hospital Clermont-Ferrand, Inserm CIC 1405, Platform of Clinical Investigation, Platform of Clinical Investigation, F-63000 Clermont-Ferrand, France.
Clinical Research and Innovation Department, University Hospital Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
J Clin Med. 2025 Jun 16;14(12):4269. doi: 10.3390/jcm14124269.
Ketamine use for chronic pain and depression has increased worldwide, but sex differences in its efficacy and safety have been little studied; this study examines existing evidence to address this gap. A prospective, multicenter, one-year observational study in 585 chronic pain patients was performed; 256 patients had one administration of ketamine and 329 had two or more. The primary outcome looked at was mean pain intensity (0-10), assessed every month for 1 year by telephone. Secondary outcomes included measures of depression and anxiety (assessed using the Hospital Anxiety and Depression Scale), quality of life (evaluated with the 12-item Short Form Health Survey), total ketamine dosage, reported adverse effects, and concomitant treatments. Platform of Clinical Investigation, No sex or age differences were observed in ketamine efficacy in terms of pain (mean variation in women vs. men; effect size -0.5 (95% confidence interval -0.6 to -0.4) vs. -0.5 (95% confidence interval -0.7 to -0.3), = 0.248) or the evolution of anxiety ( = 0.135) among the 585 patients. Women reported more adverse events than men (19% vs. 13%, = 0.002). In the subgroup of 329 patients, no differences were observed in any variables, but a single ketamine administration may be more useful in men than in women ( = 0.032), especially in younger men ( = 0.045). Repeated ketamine administration displayed no sex or age differences in efficacy in the treatment of pain, anxiety or depression.
氯胺酮用于慢性疼痛和抑郁症的治疗在全球范围内有所增加,但其疗效和安全性的性别差异鲜有研究;本研究审视现有证据以填补这一空白。对585例慢性疼痛患者进行了一项前瞻性、多中心、为期一年的观察性研究;256例患者接受了一次氯胺酮治疗,329例患者接受了两次或更多次治疗。观察的主要结局指标为平均疼痛强度(0至10分),通过电话随访对患者进行为期1年的每月评估。次要结局指标包括抑郁和焦虑测量指标(使用医院焦虑抑郁量表进行评估)、生活质量(采用12项简明健康调查问卷进行评估)、氯胺酮总剂量、报告的不良反应以及伴随治疗情况。临床研究平台,在585例患者中,氯胺酮在疼痛疗效方面未观察到性别或年龄差异(女性与男性的平均变化;效应量分别为-0.5(95%置信区间为-0.6至-0.4)与-0.5(95%置信区间为-0.7至-0.3),P = 0.248),焦虑变化情况方面也未观察到差异(P = 0.135)。女性报告的不良事件多于男性(19%对13%,P = 0.002)。在329例患者的亚组中,未观察到任何变量存在差异,但单次氯胺酮给药对男性可能比对女性更有效(P = 0.032),尤其是在年轻男性中(P = 0.045)。重复给予氯胺酮在治疗疼痛、焦虑或抑郁的疗效方面未显示出性别或年龄差异。